The puzzling inflammatory bowel disease: growing interest for mediators of inflammation

In this issue of Mediators of Inflammation two review articles and one research paper describe the local inflammation in the colon and the role of cytokines, leukocyte migration and the effect of cell–cell interaction on cytokine synthesis. In the paper by Beck and Wallace an overview is given of so far known important pro-inflammatory cytokines (IL-1, IL-2, IL-5, IL-6, IL-8, TNFα and IFNγ) and anti-inflammatory cytokines (IL-4, IL-10, IL-11, IL-13 and TGFβ). In addition the migration of leukocytes, mediated by adhesion molecules such as selectins, chemokines and integrins, is reviewed by van Rees et al. During or after this migration lymphocytes could stimulate the synthesis of the pro-inflammatory cytokines IL-2 and IFNγ, as described by Hoang et al.

Recently it has been described by Smith et al. that IL-1β stimulates the LPS-induced PGE2 synthesis by the colonocyte cell line CACO-2, whereas LTβ4 was unaffected. After simultaneous incubation with IL-1ra the elevated levels of PGE2 were completely abolished, although a significant increase in LTβ4 was observed. This could be due to the lack of feedback inhibition by substantial amounts of PGE2.

In the December 1995 issue of Mediators of Inflammation two debate articles on the involvement of nitric oxide as pro- or anti-inflammatory mediator were published, again reflecting Janus, the symbol for mediators of inflammation, which exert both harmful and beneficial functions.

In summary, from the above-mentioned findings it could be concluded that in inflammatory bowel disease (IBD) mediators of inflammation are involved which could be considered as (a) pro- or anti-inflammatory mediators, (b) primary or secondary mediators, (c) proteins, lipid mediators or otherwise, (d) Th1- or Th2-cell derived substances. Furthermore migrated cells could amplify synthesis of mediators by cells localized in the lamina propria. Moreover one should consider that IBD include two different diseases (Crohn’s disease and ulcerative colitis) which, though displaying similar aspects of inflammatory features in the colon, nevertheless require distinct medical treatment.

The adequate therapy of patients not responding to classical treatment with corticosteroids nowadays includes the experimental use of anti-TNFα and IL-10 in Crohn’s disease, whereas nicotine also has proven to be beneficial in ulcerative colitis. Such treatment regimens imply knowledge about mechanisms of action underlying biochemical aspects of acute, sub-acute and chronic phenomena of colonic inflammation.

So far we may conclude that corticosteroids will suppress all mediators, whereas 5-aminosalicylic acid (5-ASA) partly attenuates cytokine synthesis. Although nicotine probably acts through inhibition of eicosanoids and pro-inflammatory cytokines, it is not yet clear why nicotine (including the otherwise harmful habit of smoking) is good for ulcerative colitis and bad for Crohn’s disease. This could be related to the Th1- and Th2-cell specific aspects seen in IBD. On the other hand conflicting results were obtained from investigations in Crohn’s disease and ulcerative colitis in which IFNγ, IL-2 and IL-10 were all increased.

Up to now it is not quite clear whether nicotine selectively inhibits pro-inflammatory cytokines derived from Th1-cells or not, since we observed that IL-10 was decreased after nicotine in vivo.

Finally cyclosporin has been reported to be effective in IBD. Both T cell proliferation and the production of T cell-derived cytokines is inhibited. The reduction of T cell migration might be another fruitful area for future studies.

Knowledge of the potential T cell subsets to
generate pro- and anti-inflammatory cytokines in IBD, which in turn affect secondary mediators such as eicosanoids, could contribute to the understanding of these puzzling diseases and subsequently lead to the development of more adequate medicines to prevent severe exacerbations during the chronic phase of the disease.

Submission of research papers on this subject would be welcomed for forthcoming issues of *Mediators of Inflammation*.

Dr F.J. Zijlstra
Assistant Editor Department of Pharmacology, Faculty of Medicine and Health Sciences, Erasmus University, PO. Box 1738, 3000 DR Rotterdam, The Netherlands Fax: (+33) 10 436 6839; Email: zijlstra@farm.fgg.eur.nl

References

Submit your manuscripts at http://www.hindawi.com